China Market Intelligence

July 22nd, 2015
Owen Haacke

Fewer restrictions on drug pricing and greater access for foreign companies may make for a healthier China, and bring both potential growth and growing pains to the pharmaceutical industry—a sector analysts expect to be worth upwards of $300 billion by 2020.

May 27th, 2015
Ryan Ong

More and more US companies have active research and development (R&D) operations in China, and many have seen these operations evolve from small groups primarily focused on product localization to globally significant operations conducting cutting-edge R&D for the China market.

Congressional Legislative Tracker

The USCBC Government Affairs team continuously monitors China-related bills and broader legislative trends spanning a variety of issue areas, including trade and investment, national security, telecommunications, and human rights.

LEARN MORE